Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Drug/Agent Toxicity by Tissue/Organ: early-phase trial registry

A small indexed set (3 trials) with no open enrollment listed right now.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count

Drug/Agent Toxicity by Tissue/Organ: 3 US clinical trials tracked, none currently recruiting.

Drug/Agent Toxicity by Tissue/Organ is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, running 1 of these trials.

Enrollment posture brief

Registry condition drugagent-toxicity-by-tissueorgan

OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Drug/Agent Toxicity by T (th…0%
Open-enrollment share among volume-matched conditions near Drug/Agent Toxicity by Tissue/Organ

Drug/Agent Toxicity by Tissue/Organ has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Drug/Agent Toxicity by Tissue/Organ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Drug/Agent Toxicity by Tissue/Organ is recruiting below its size-band peers.

    0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 13

Phase Distribution

PhaseTrial count
Phase 1 3

Named interventions

Most-linked intervention names on Drug/Agent Toxicity by Tissue/Organ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

amifostine trihydrate Drug
2 trials
phenobarbital Drug
1 trials
cyclosporine Drug
1 trials
irinotecan hydrochloride Drug
1 trials
idarubicin Drug
1 trials
cytarabine Drug
1 trials
filgrastim Biological
1 trials
etoposide Drug
1 trials

US sites by state

Facility locations filed on Drug/Agent Toxicity by Tissue/Organ trials. A trial with sites in several states counts in each.

Illinois 2 trials
Pennsylvania 1 trials
Florida 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Drug/Agent Toxicity by Tissue/Organ page

3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug/Agent Toxicity by Tissue/Organ condition card totals 3 registered trials; most-linked intervention amifostine trihydrate; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.